Webinar: Utilizing Synthetic DNA Technologies for High Throughput Antibody Discovery and Optimization
G-protein coupled receptors (GPCRs) are transmembrane proteins involved in numerous signaling pathways. They are the largest and most diverse group of membrane receptors, they are important, but are difficult-to-target.
GPCRs have low expression levels in cells and only a small portion of the protein is exposed on the surface of the cell membrane. This creates challenges in developing antibodies against GPCRs. It is even more difficult to develop monoclonal antibodies that are functional.
Utilizing its proprietary DNA technology to write synthetic libraries, Twist Biopharma provide end-to-end antibody discovery and optimization solutions.
To enable the discovery of functional GPCR (G protein-coupled receptor) antibodies, they grafted a large number of GPCR-binding motifs into a focused antibody library. By incorporating these motifs into the antibody heavy chain CDR3, they developed a first generation GPCR library.
Another approach mined the patented GPCR antibody sequences, and used the sequence information to guide the design of another synthetic library. Twist Biopharma demonstrate the utility of both libraries to discover potent functional antibodies against multiple GPCR targets.
Key webinar discussion topics include:
- A brief background to GPCR libraries
- Illustration of how these libraries are utilized in conjunction with high-throughput cell binding assays (iQue® Advanced Flow Cytometry Platform) and functional assays.
About the speaker
Aaron K. Sato, Ph.D.
Chief Scientific Officer
Biopharma, Twist Bioscience
Aaron is CSO and head of the Biopharma Vertical at Twist Bioscience. Prior to Twist, he served as Chief Scientific Officer of LakePharma, leading the California Antibody Center, which discovers novel antibody therapeutics for its clients. He also oversaw all discovery research functions both as Vice President of Protein Sciences at Surrozen, and previously, as Vice President of Research at Sutro Biopharma, Inc. He also held director level positions at both Oncomed and Dyax Corp.